Alex Goldberg

Cannabis Science, Inc. (OTC:CBIS) and Hemp, Inc. (OTC:HEMP) Added to Equity Profile Report's OTC Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 01/02/2014 -- Equity Profile Report expands its OTC Gainers Weekly Watch List adding Cannabis Science, Inc. (OTC:CBIS) and Hemp, Inc. (OTC:HEMP).

Cannabis Science, Inc. (OTC:CBIS) a development stage company that engages in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products is currently up (+29.32%) on 18,891,989 shares traded. Cannabis Science, Inc. (OTC:CBIS) is currently up (+133.33%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their OTC Gainers Watch List.

Click Here to find out what other Investors are saying about Cannabis Science, Inc. (OTC:CBIS)

Hemp, Inc. (OTC:HEMP) a company that focuses on supplying services, products, and information related to the medical marijuana industry or to those who have an affinity for the medical marijuana industry is currently up (+53.77%) on 37,562,732 shares traded after Hemp, Inc. Reviewed the Industrial Hemp Industry in 2013. Hemp, Inc. (OTC:HEMP) is currently up (+200%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their OTC Gainers Watch List.

Click Here to find out what other Investors are saying about Hemp, Inc. (OTC:HEMP)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com